News & Events about Intercept Pharmaceuticals Inc.
Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT Get Rating) B. Riley raised their FY2023 earnings estimates for shares of Intercept Pharmaceuticals in a report issued on Monday, April 24th. B. Riley analyst M. Mamtani now forecasts that the biopharmaceutical company will earn $0.19 per share for the ...
Globe Newswire
2 months ago
Advisory Committee Meeting scheduled for May 19, 2023 PDUFA Target Action Date is June 22, 2023 MORRISTOWN, N.J., March 10, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to ...
Globe Newswire
2 months ago
MORRISTOWN, N.J., March 09, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that it will be participating in ...
Globe Newswire
3 months ago
U.S. Ocaliva net sales of $77.2 million and $285.7 million for the fourth quarter and full year 2022, representing 13% and 10% growth over the prior year Worldwide Ocaliva non-GAAP adjusted net sales of $343.8 million for the full year 2022 As of December 31, 2022, Company has cash, cash equivalents...
Globe Newswire
3 months ago
MORRISTOWN, N.J., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that Jerry Durso, President and Chief ...